{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:18:12Z","timestamp":1783592292317,"version":"3.55.0"},"reference-count":13,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Clinical outcomes remain heterogeneous among patients with unresectable stage III non-small cell lung cancer treated with definitive chemoradiotherapy. We evaluated the prognostic value of the systemic immune-inflammation index (SII) and explored survival outcomes according to the concurrent chemotherapy backbone in this setting. This retrospective study included 101 patients treated with definitive chemoradiotherapy before consolidation durvalumab became standard practice. Baseline SII was calculated using routine blood counts. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan\u2013Meier method and Cox proportional hazards models. With a median follow-up of 40.6 months, patients with low SII had significantly longer OS (26.1 vs. 10.9 months, p = 0.004) and PFS (15.6 vs. 7.2 months, p = 0.018) than those with high SII. Elevated SII remained independently associated with inferior OS in multivariable analysis (HR 1.99, 95% CI 1.21\u20133.27, p = 0.007). Although survival was numerically longer with cisplatin\/etoposide than with carboplatin\/paclitaxel, the difference was not statistically significant. Subgroup analysis according to SII level and chemotherapy regimen showed the poorest outcomes among patients with high SII receiving carboplatin\/paclitaxel. These findings support the prognostic value of SII and suggest a potential role for risk stratification in patients with unresectable stage III NSCLC undergoing definitive chemoradiotherapy in the pre-durvalumab era.<\/jats:p>","DOI":"10.3390\/curroncol33070407","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T08:50:56Z","timestamp":1783587056000},"page":"407","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Impact of the Systemic Immune-Inflammation Index According to Concurrent Chemotherapy Backbone in Stage III Non-Small Cell Lung Cancer"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2842-4695","authenticated-orcid":false,"given":"Aykut","family":"Demirk\u0131ran","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Konya City Hospital, 42090 Konya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Araz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University, 42080 Konya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek Karakurt","family":"Ery\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University, 42080 Konya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Karaa\u011fa\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Medical Park Hospital, 55200 Samsun, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Muhiddin","family":"Er","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Konya City Hospital, 42090 Konya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berrin Benli","family":"Yavuz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Necmettin Erbakan University, 42080 Konya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Arta\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University, 42080 Konya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11795549231152948","DOI":"10.1177\/11795549231152948","article-title":"Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer","volume":"17","author":"Baudoux","year":"2023","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Rolland","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cac2.12505","article-title":"Management of locally advanced non-small cell lung cancer: State of the art and future directions","volume":"44","author":"Miao","year":"2024","journal-title":"Cancer Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-14-0442","article-title":"Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma","volume":"20","author":"Hu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.7150\/jca.25691","article-title":"Prognostic Value of Systemic Immune-Inflammation Index in Cancer: A Meta-Analysis","volume":"9","author":"Yang","year":"2018","journal-title":"J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.21037\/atm.2019.08.116","article-title":"Prognostic Value of the Pretreatment Systemic Immune-Inflammation Index (SII) in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis","volume":"7","author":"Wang","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12967-017-1326-1","article-title":"Systemic Immune-Inflammation Index Predicting Chemoradiation Resistance and Poor Outcome in Patients with Stage III Non-Small Cell Lung Cancer","volume":"15","author":"Tong","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/annonc\/mdx009","article-title":"Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: A multicenter randomized phase III trial","volume":"28","author":"Liang","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5306\/wjco.v8.i1.1","article-title":"Therapeutic management options for stage III non-small cell lung cancer","volume":"8","author":"Yoon","year":"2017","journal-title":"World J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yang, Y., Li, J., Wang, Y., Luo, L., Yao, Y., and Xie, X. (2024). Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0312605"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/407\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:36:06Z","timestamp":1783589766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":13,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["curroncol33070407"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33070407","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]}}}